BEAM240517P12500
- 0.30
- 0.000.00%
Beam Therapeutics Newsroom
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will report
Analysts' Opinions Are Mixed on These Healthcare Stocks: Beam Therapeutics (BEAM), Cormedix (CRMD) and Applied Therapeutics (APLT)
Beam Therapeutics: A Hold Rating Amid Controlled R&D Spending and Upcoming Clinical Milestones
Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Beam Therapeutics (BEAM) and Mirum Pharmaceuticals (MIRM)
Beam Therapeutics Price Target Cut to $33.00/Share From $42.00 by Barclays
Beam Therapeutics Price Target Cut to $33.00/Share From $42.00 by Barclays
Beam Therapeutics Is Maintained at Equal-Weight by Barclays
Beam Therapeutics Is Maintained at Equal-Weight by Barclays
Barclays Maintains Equal-Weight on Beam Therapeutics, Lowers Price Target to $33
Barclays analyst Gena Wang maintains Beam Therapeutics with a Equal-Weight and lowers the price target from $42 to $33.
Beam Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 50.75% Barclays $42 → $33 Maintains Equal-Weight 04/23/2024 160.39% Wedbush → $57 Reiterates Ou
Beam Therapeutics: A Strong Buy on Breakthrough Potential and Financial Stability
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief
Analysts' Opinions Are Mixed on These Healthcare Stocks: Beam Therapeutics (BEAM), Travere Therapeutics (TVTX) and Oscar Health (OSCR)
Beam Therapeutics Inc (BEAM) Reports Q1 2024 Earnings: A Detailed Overview
Analysts Offer Insights on Healthcare Companies: Esperion (ESPR) and Beam Therapeutics (BEAM)
Beam Therapeutics Shares Fall After Q1 Revenue Misses Estimates
Beam Therapeutics (BEAM) shares slid 3.6% in recent Tuesday trading after the company reported Q1 revenue that missed analysts' estimates. The company reported a Q1 net loss Tuesday of $1.21 per dilut
Beam Therapeutics | 10-Q: Quarterly report
Beam Therapeutics Ended Q1 2024 With $1.1B In Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans Into 2027
Beam Therapeutics Ended Q1 2024 With $1.1B In Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans Into 2027
Beam Therapeutics Q1 2024 GAAP EPS $(1.21) Beats $(1.44) Estimate, Sales $7.410M Miss $16.967M Estimate
Beam Therapeutics Q1 2024 GAAP EPS $(1.21) Beats $(1.44) Estimate, Sales $7.410M Miss $16.967M Estimate
Beam Therapeutics 1Q Loss/Shr $1.21 >BEAM
Beam Therapeutics 1Q Loss/Shr $1.21 >BEAM
Press Release: Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results Dosing Completed for Sentinel Cohort of BEACON Phase 1/2 Trial of BEAM-101 in Severe Sickle Cell Disease; Expansion
Benign Growth For Beam Therapeutics Inc. (NASDAQ:BEAM) Underpins Stock's 30% Plummet
Beam Therapeutics Inc. (NASDAQ:BEAM) shareholders won't be pleased to see that the share price has had a very rough month, dropping 30% and undoing the prior period's positive performance. Instead